CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $250.05M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 2.77: safe zone
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
5.45%Above 5Y avg (3.04%)
Annual Rate
TWD 4.50Paid annual
Payout Ratio
71.8%Moderate
Payback Period
18.3 yr
Last Ex-Dividend
Jul 23, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
7.96BTWD250.05M · vs all stocks (USD)
Trailing P/E
14.90xvs Medical Devices peers
Revenue (TTM)
6.07BTWD190.68M · vs all stocks (USD)
Profit Margin
9.09%vs Medical Devices peers
Beta
0.4110xvs all stocks
52-Week Change
-28.26%vs all stocks
Market Capitalization
7.96BTWD250.05M · vs all stocks (USD)
Enterprise Value
9.89BTWD310.69M · vs all stocks (USD)
Trailing P/E
14.90xvs Medical Devices peers
Forward P/E
11.76xvs Medical Devices peers
PEG Ratio
0.0745xvs Medical Devices peers
Price to Sales (TTM)
1.32xvs Medical Devices peers
Price to Book (MRQ)
2.05xvs Medical Devices peers
Enterprise to Revenue
1.63xvs Medical Devices peers
Enterprise to EBITDA
8.02xvs Medical Devices peers
Gross Margin
78.48%vs Medical Devices peers
Profit Margin
9.09%vs Medical Devices peers
Operating Margin
12.02%vs Medical Devices peers
Return on Assets (TTM)
5.56%vs Medical Devices peers
Return on Equity (TTM)
14.28%vs Medical Devices peers
Revenue (TTM)
6.07BTWD190.68M · vs all stocks (USD)
Revenue per Share (TTM)
62.91TWDUpdated Sep 21, 2026Quarterly Revenue Growth
15.90%vs Medical Devices peers
Gross Profit (TTM)
4.74BTWD149.08M · vs all stocks (USD)
EBITDA (TTM)
1.36BTWD42.90M · vs all stocks (USD)
Net Income (TTM)
551.28MTWD17.33M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
197.90%vs Medical Devices peers
Operating Cash Flow (TTM)
742.69MTWD23.34M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-235.03MTWD-7.39M · vs all stocks (USD)
Trailing Annual Dividend Rate
4.50TWDUpdated Sep 21, 2026Trailing Annual Dividend Yield
5.45%vs all stocks
5-Year Average Dividend Yield
3.04%vs all stocks
Payout Ratio
71.82%vs Medical Devices peers
Minority Interest (Equity)
104.73MTWDFY2025 · Dec 31, 2025Revenue
5.66BTWDFY2025 · Dec 31, 2025Cost of Goods Sold
1.26BTWDFY2025 · Dec 31, 2025Gross Profit
4.40BTWDFY2025 · Dec 31, 2025Operating Income
736.70MTWD23.15M · vs all stocks (USD)
Pre-tax Income
756.40MTWDFY2025 · Dec 31, 2025Income Tax Expense
184.93MTWDFY2025 · Dec 31, 2025Net Income
571.47MTWDFY2025 · Dec 31, 2025EBIT
802.35MTWDFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.34BTWDFY2025 · Dec 31, 2025Research & Development
262.54MTWDFY2025 · Dec 31, 2025Selling, General & Administrative
3.40BTWDFY2025 · Dec 31, 2025Non-operating Interest Income
15.52MTWDFY2025 · Dec 31, 2025Non-operating Interest Expense
45.95MTWDFY2025 · Dec 31, 2025Minority Interests (P&L)
-8.97MTWDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00TWDFY2025 · Dec 31, 2025Operating Cash Flow
393.77MTWDFY2025 · Dec 31, 2025Free Cash Flow
-259.94MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
662.81MTWDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
756.40MTWDFY2025 · Dec 31, 2025Other Non-cash Items
23.01MTWDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-151.54MTWDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-234.10MTWDFY2025 · Dec 31, 2025Capital Expenditures
-653.71MTWDFY2025 · Dec 31, 2025Net Intangibles (CF)
-74.08MTWDFY2025 · Dec 31, 2025Purchase of Investments
-6.26MTWDFY2025 · Dec 31, 2025Sale of Investments
13.31MTWDFY2025 · Dec 31, 2025Other Investing Activity
5.82MTWDFY2025 · Dec 31, 2025Net Investing Cash Flow
-640.84MTWDFY2025 · Dec 31, 2025Long-term Debt Issuance
708.47MTWDFY2025 · Dec 31, 2025Long-term Debt Payments
-4.60BTWDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-243.09MTWDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00TWDFY2025 · Dec 31, 2025Common Dividends Paid
-385.87MTWDFY2025 · Dec 31, 2025Other Financing Charges
-531.00KTWDFY2025 · Dec 31, 2025Net Financing Cash Flow
-4.52BTWDFY2025 · Dec 31, 2025Shares Outstanding
96.44MSharesUpdated Sep 21, 2026Float Shares
77.38MSharesUpdated Sep 21, 2026% Held by Insiders
34.64%vs all stocks
% Held by Institutions
2.12%vs all stocks
Total Cash (MRQ)
579.93MTWD18.23M · vs all stocks (USD)
Total Cash per Share (MRQ)
6.01TWDUpdated Sep 21, 2026Total Debt (MRQ)
2.36BTWD74.14M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5890xvs Medical Devices peers
Current Ratio (MRQ)
1.43xvs Medical Devices peers
Book Value per Share (MRQ)
40.47TWDUpdated Sep 21, 2026Total Assets
7.82BTWD245.84M · vs all stocks (USD)
Total Current Assets
4.29BTWDFY2025 · Dec 31, 2025Total Liabilities
3.62BTWDFY2025 · Dec 31, 2025Total Non-current Assets
3.53BTWDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.12BTWDFY2025 · Dec 31, 2025Total Current Liabilities
2.50BTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents
662.81MTWDFY2025 · Dec 31, 2025Accounts Receivable
1.30BTWDFY2025 · Dec 31, 2025Inventory
2.07BTWDFY2025 · Dec 31, 2025Accounts Payable
213.51MTWDFY2025 · Dec 31, 2025Short-term Debt
1.06BTWDFY2025 · Dec 31, 2025Other Current Liabilities
51.03MTWDFY2025 · Dec 31, 2025Long-term Debt
1.00BTWDFY2025 · Dec 31, 2025Other Non-current Liabilities
8.22MTWDFY2025 · Dec 31, 2025Common Stock (Book)
964.38MTWDFY2025 · Dec 31, 2025Retained Earnings
629.95MTWDFY2025 · Dec 31, 2025Total Shareholders' Equity
4.20BTWD132.14M · vs all stocks (USD)
52-Week Low
81.00TWDUpdated Sep 21, 202652-Week High
131.50TWDUpdated Sep 21, 202652-Week Change
-28.26%vs all stocks
Beta
0.4110xvs all stocks
50-Day MA
85.57TWDUpdated Sep 21, 2026200-Day MA
98.83TWDUpdated Sep 21, 2026Avg 10-Day Volume
154.77KSharesUpdated Sep 21, 2026Avg 30-Day Volume
287.70KSharesUpdated Sep 21, 2026Diluted EPS (TTM)
5.57TWDUpdated Sep 21, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
How is this stock valued?
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.77: safe zoneNotable
Altman Z-Score: 2.77
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $250.05M, lower than 95% of all stocks globallySignificant
Market cap (USD): 250,053,366.915Global P5: 275,556,405.438
Companies that share the same coordination system — how they create, deliver, or capture value.
Acimmune SA
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Daito Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Akebia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
PharmaEngine, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Heartseed Inc.
Tier 1ProductionApproval-Gated PipelineRule
Siga Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Palisade Bio Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sisram Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Seikagaku Corporation
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Keli Sensing Technology Nanjing Inc.
4 interpretationsRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedPrice Below Mean With Profitability And Book Value
Waste Connections Inc.
4 interpretationsRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedPrice Below Mean With Profitability And Book Value
Spx Technologies Inc.
4 interpretationsRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedPrice Below Mean With Profitability And Book Value